oxiracetam has been researched along with Dementia in 7 studies
oxiracetam: structure in first source
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effectiveness of Oxiracetam (1600 mg/day) versus placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia." | 9.07 | Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy. ( Bianchetti, A; Rozzini, R; Zanetti, O, 1993) |
| "The effectiveness of oxiracetam (1600 mg/day) vs placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia." | 9.07 | Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia. ( Bianchetti, A; Rozzini, R; Zanetti, O, 1992) |
| "Oxiracetam is a recently synthesized nootropic that was tested as a potential treatment for cognitive decline in patients with multi-infarct dementia (MID) and primary degenerative dementia (PDD)." | 9.06 | Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia. ( Dysken, MW; Katz, R; Kuskowski, M; Stallone, F, 1989) |
| "A multicentre, double-blind, between-patient study was carried out to evaluate the efficacy and tolerability of oxiracetam (800-mg tablets), in comparison with placebo, each given twice daily for 12 weeks to patients suffering from primary degenerative, multi-infarct or mixed forms of dementia." | 9.06 | Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. ( Bonavita, E; Fagiani, MB; Ferrario, E; Fiori, L; Ghiazza, B; Maina, G; Ravizza, L; Teruzzi, F; Torta, R; Zagnoni, PG, 1989) |
| "40 out-patients with a mild to moderate degree of dementia (11 less than or equal to MMSE less than 24) participated in a between-subjects (n = 20 + 20) double-blind placebo-controlled randomized trial comparing the effects of oxiracetam 800 mg bid and placebo during 90 days of treatment." | 9.06 | Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia. ( Grioli, S; Lomeo, C; Parini, J; Quattropani, M; Scapagnini, U; Villardita, C, 1987) |
| "The effectiveness of Oxiracetam (1600 mg/day) versus placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia." | 5.07 | Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy. ( Bianchetti, A; Rozzini, R; Zanetti, O, 1993) |
| "The effectiveness of oxiracetam (1600 mg/day) vs placebo was assessed in a group of 96 out-patients suffering from cognitive disorders secondary to primary degenerative dementia." | 5.07 | Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia. ( Bianchetti, A; Rozzini, R; Zanetti, O, 1992) |
| "Oxiracetam is a recently synthesized nootropic that was tested as a potential treatment for cognitive decline in patients with multi-infarct dementia (MID) and primary degenerative dementia (PDD)." | 5.06 | Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia. ( Dysken, MW; Katz, R; Kuskowski, M; Stallone, F, 1989) |
| "A multicentre, double-blind, between-patient study was carried out to evaluate the efficacy and tolerability of oxiracetam (800-mg tablets), in comparison with placebo, each given twice daily for 12 weeks to patients suffering from primary degenerative, multi-infarct or mixed forms of dementia." | 5.06 | Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. ( Bonavita, E; Fagiani, MB; Ferrario, E; Fiori, L; Ghiazza, B; Maina, G; Ravizza, L; Teruzzi, F; Torta, R; Zagnoni, PG, 1989) |
| "40 out-patients with a mild to moderate degree of dementia (11 less than or equal to MMSE less than 24) participated in a between-subjects (n = 20 + 20) double-blind placebo-controlled randomized trial comparing the effects of oxiracetam 800 mg bid and placebo during 90 days of treatment." | 5.06 | Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia. ( Grioli, S; Lomeo, C; Parini, J; Quattropani, M; Scapagnini, U; Villardita, C, 1987) |
| "Oxiracetam, a new substance found to be a nootropic in experimental pharmacological studies, was tested in three clinical trials: a single rising dose tolerance and dose-finding study with quantitative pharmaco-electroencephalogram (pharmaco-EEG) and quantitative pharmacopsychology in healthy volunteers; a dose-finding study, at three dose levels for 3 months, with quantitative pharmaco-EEG in mild to moderate dementia patients; and a safety and efficacy study with increasing dosages for 12 weeks with subjective and objective tests in elderly patients with dementia." | 3.67 | CNS pharmacology and clinical therapeutic effects of oxiracetam. ( Itil, KZ; Itil, TM; Menon, GN; Songar, A, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (71.43) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rozzini, R | 2 |
| Zanetti, O | 2 |
| Bianchetti, A | 2 |
| Dysken, MW | 1 |
| Katz, R | 1 |
| Stallone, F | 1 |
| Kuskowski, M | 1 |
| Gava, R | 1 |
| Schifano, F | 1 |
| Maina, G | 1 |
| Fiori, L | 1 |
| Torta, R | 1 |
| Fagiani, MB | 1 |
| Ravizza, L | 1 |
| Bonavita, E | 1 |
| Ghiazza, B | 1 |
| Teruzzi, F | 1 |
| Zagnoni, PG | 1 |
| Ferrario, E | 1 |
| Villardita, C | 1 |
| Parini, J | 1 |
| Grioli, S | 1 |
| Quattropani, M | 1 |
| Lomeo, C | 1 |
| Scapagnini, U | 1 |
| Itil, TM | 1 |
| Menon, GN | 1 |
| Songar, A | 1 |
| Itil, KZ | 1 |
1 review available for oxiracetam and Dementia
| Article | Year |
|---|---|
[Oxiracetam].
Topics: Adult; Aged; Animals; Cerebrovascular Disorders; Clinical Trials as Topic; Dementia; Dogs; Humans; M | 1989 |
6 trials available for oxiracetam and Dementia
| Article | Year |
|---|---|
Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy.
Topics: Aged; Ambulatory Care; Cognition Disorders; Dementia; Double-Blind Method; Female; Humans; Male; Neu | 1993 |
Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Dementia; Double-Blind Method; Female; Humans; Male; N | 1992 |
Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Dementia; Dementia, Multi-Infarct; Dose-Respons | 1989 |
[Oxiracetam].
Topics: Adult; Aged; Animals; Cerebrovascular Disorders; Clinical Trials as Topic; Dementia; Dogs; Humans; M | 1989 |
Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Dementia; Dementia, Multi-Infarct; Double-Blind Method; Female; Humans; Mal | 1989 |
Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia.
Topics: Aged; Cognition; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Pyrrolidines | 1987 |
1 other study available for oxiracetam and Dementia
| Article | Year |
|---|---|
CNS pharmacology and clinical therapeutic effects of oxiracetam.
Topics: Brain; Dementia; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Electroencephal | 1986 |